clinical trial · NCT06282159
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Myasthenia Gravis, GeneralizedClaseprubartPlacebo
brief summary
The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
started
Feb 23, 2024
primary completion
Jul 28, 2025
completion
Oct 1, 2028
last updated
Jun 8, 2026
detailed description
The study includes the following periods:
* Screening (up to 10 weeks) * Randomized, blinded, controlled treatment (RCT) period (13 weeks) * Open-label extension (OLE) period (optional) for eligible participants (104 weeks) * Safety follow-up (SFU) (40 weeks)
official title
A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol